| ［1］ |
Stang A, Becker JC, Nghiem P, et al. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: an international assessment［J］. Eur J Cancer, 2018,94:47⁃60. doi: 10.1016/j.ejca.2018.02.003.
|
| ［2］ |
王志伟, 李伟人, 刘莉, 等. 皮肤Merkel细胞癌171例临床及病理回顾分析［J］. 中华皮肤科杂志, 2018,51（9）:695⁃698. doi: 10.3760/cma.j.issn.0412⁃4030.2018.09.020.
|
| ［3］ |
Walsh NM, Cerroni L. Merkel cell carcinoma: a review［J］. J Cutan Pathol, 2021,48（3）:411⁃421. doi: 10.1111/cup.13910.
|
| ［4］ |
Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma［J］. Science, 2008,319（5866）:1096⁃1100. doi: 10.1126/science.1152586.
|
| ［5］ |
Zur Hausen A, Rennspiess D, Winnepenninckx V, et al. Early B⁃cell differentiation in Merkel cell carcinomas: clues to cellular ancestry［J］. Cancer Res, 2013,73（16）:4982⁃4987. doi: 10. 1158/0008⁃5472.CAN⁃13⁃0616.
|
| ［6］ |
Sunshine JC, Jahchan NS, Sage J, et al. Are there multiple cells of origin of Merkel cell carcinoma?［J］. Oncogene, 2018,37（11）:1409⁃1416. doi: 10.1038/s41388⁃017⁃0073⁃3.
|
| ［7］ |
Kervarrec T, Aljundi M, Appenzeller S, et al. Polyomavirus⁃positive Merkel cell carcinoma derived from a trichoblastoma suggests an epithelial origin of this Merkel cell carcinoma［J］. J Invest Dermatol, 2020,140（5）:976⁃985. doi: 10.1016/j.jid.2019. 09.026.
|
| ［8］ |
Poulsen M. Merkel cell carcinoma of skin: diagnosis and management strategies［J］. Drugs Aging, 2005,22（3）:219⁃229. doi: 10.2165/00002512⁃200522030⁃00004.
|
| ［9］ |
Lebbe C, Becker JC, Grob JJ, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus⁃based interdisciplinary guideline［J］. Eur J Cancer, 2015,51（16）:2396⁃2403. doi: 10.1016/j.ejca.2015.06.131.
|
| ［10］ |
Stachyra K, Dudzisz⁃Śledź M, Bylina E, et al. Merkel cell carcinoma from molecular pathology to novel therapies［J］. Int J Mol Sci, 2021,22（12）:6305. doi: 10.3390/ijms22126305.
|
| ［11］ |
Poulsen M. Merkel⁃cell carcinoma of the skin［J］. Lancet Oncol, 2004,5（10）:593⁃599. doi: 10.1016/S1470⁃2045（04）01593⁃1.
|
| ［12］ |
Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma［J］. Nat Rev Dis Primers, 2017,3:17077. doi: 10.1038/nrdp. 2017.77.
|
| ［13］ |
Xue Y, Thakuria M. Merkel cell carcinoma review［J］. Hematol Oncol Clin North Am, 2019,33（1）:39⁃52. doi: 10.1016/j.hoc. 2018.08.002.
|
| ［14］ |
Babadzhanov M, Doudican N, Wilken R, et al. Current concepts and approaches to Merkel cell carcinoma［J］. Arch Dermatol Res, 2021,313（3）:129⁃138. doi: 10.1007/s00403⁃020⁃02107⁃9.
|
| ［15］ |
Moshiri AS, Doumani R, Yelistratova L, et al. Polyomavirus⁃negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection［J］. J Invest Dermatol, 2017,137（4）:819⁃827. doi: 10.1016/j.jid.2016.10.028.
|
| ［16］ |
Eng TY, Boersma MG, Fuller CD, et al. Treatment of Merkel cell carcinoma［J］. Am J Clin Oncol, 2004,27（5）:510⁃515. doi: 10. 1097/01.coc.0000135567.62750.f4.
|
| ［17］ |
Andruska N, Fischer⁃Valuck BW, Mahapatra L, et al. Association between surgical margins larger than 1 cm and overall survival in patients with Merkel cell carcinoma［J］. JAMA Dermatol, 2021,157（5）:540⁃548. doi: 10.1001/jamadermatol. 2021.0247.
|
| ［18］ |
Servy A, Maubec E, Sugier PE, et al. Merkel cell carcinoma: value of sentinel lymph⁃node status and adjuvant radiation therapy［J］. Ann Oncol, 2016,27（5）:914⁃919. doi: 10.1093/annonc/mdw035.
|
| ［19］ |
Sims JR, Grotz TE, Pockaj BA, et al. Sentinel lymph node biopsy in Merkel cell carcinoma: the Mayo Clinic experience of 150 patients［J］. Surg Oncol, 2018,27（1）:11⁃17. doi: 10.1016/j.suronc.2017.10.005.
|
| ［20］ |
Yusuf M, Gaskins J, Wall W, et al. Optimal adjuvant radiotherapy dose for stage I, II or III Merkel cell carcinoma: an analysis of the national cancer database［J］. Jpn J Clin Oncol, 2020,50（2）:175⁃184. doi: 10.1093/jjco/hyz153.
|
| ［21］ |
Dellambra E, Carbone ML, Ricci F, et al. Merkel cell carcinoma［J］. Biomedicines, 2021,9（7）:718. doi: 10.3390/biomedicines 9070718.
|
| ［22］ |
Harms PW, Harms KL, Moore PS, et al. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities［J］. Nat Rev Clin Oncol, 2018,15（12）:763⁃776. doi: 10.1038/s41571⁃018⁃0103⁃2.
|
| ［23］ |
Samimi M, Kervarrec T, Touze A. Immunobiology of Merkel cell carcinoma［J］. Curr Opin Oncol, 2020,32（2）:114⁃121. doi: 10. 1097/CCO.0000000000000608.
|
| ［24］ |
Ah⁃Thiane L, Samimi M, Kervarrec T, et al. Complete spontaneous regression of primary Merkel cell carcinoma with tumoural infiltration: a systematic review［J］. Eur J Dermatol, 2021,31（3）:381⁃391. doi: 10.1684/ejd.2021.4065.
|
| ［25］ |
Bhanegaonkar A, Liu FX, Boyd M, et al. Real⁃world clinical outcomes in patients with locally advanced or metastatic Merkel cell carcinoma treated in U.S. oncology clinical practices: results from SPEAR⁃Merkel［J］. Oncologist, 2021,26（9）:e1633⁃e1643. doi: 10.1002/onco.13845.
|
| ［26］ |
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy⁃refractory metastatic Merkel cell carcinoma: a multicentre, single⁃group, open⁃label, phase 2 trial［J］. Lancet Oncol, 2016,17（10）:1374⁃1385. doi: 10.1016/S1470⁃2045（16）30364⁃3.
|
| ［27］ |
Nghiem P, Bhatia S, Lipson EJ, et al. Three⁃year survival, correlates and salvage therapies in patients receiving first⁃line pembrolizumab for advanced Merkel cell carcinoma［J］. J Immunother Cancer, 2021,9（4）:e002478. doi: 10.1136/jitc⁃2021⁃002478.
|
| ［28］ |
Nghiem P, Bhatia S, Lipson EJ, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first⁃line therapy［J］. J Clin Oncol, 2019,37（9）:693⁃702. doi: 10.1200/JCO.18.01896.
|
| ［29］ |
Stege HM, Haist M, Schultheis S, et al. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study［J］. Cancer Immunol Immunother, 2021,70（11）:3313⁃3322. doi: 10.1007/s00262⁃021⁃02925⁃4.
|
